Biotech Halftime Report: A Winding Road Ahead

Update: 2023-09-26

Description

Join Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023.

Comments

In Channel

Business Jets: Market Dynamics Support Continued Growth

2024-08-1515:59

Why Fintechs’ Mood is More Upbeat than the Market’s

2024-08-1520:50

Power, Utilities & Infrastructure: Powering global datacenter growth

2024-08-0915:28

GenAI Activated: Key Debates and Topics in Software

2024-07-2419:16

UK Banks - 2024, Year of the Caterpillar

2024-03-2511:06

Energy Insights: M&A – What’s Next?

2024-03-1109:13

A Climate of Change for Nuclear Energy

2024-02-1614:00

2024 Global Banks Research Outlook

2024-01-2613:27

The Race is on to Provide 32 Million EV Charge Points

2023-11-1016:39

Status of carbon capture in Europe and the US

2023-10-2414:56

Biotech Halftime Report: A Winding Road Ahead

2023-09-2617:40

Energy Insights: Canada’s Trans Mountain Pipeline Expansion

2023-08-1513:50

Aerospace: Can Supply Keep Up with Demand?

2023-08-1019:35

Charting the Robotaxi Revolution

2023-07-2616:36

Generative AI set to reshape the Customer Service industry?

2023-07-2617:25

What are the Strategic Priorities for Fintech?

2023-07-1816:00

Generative AI takes center stage

2023-06-3020:13

The Rise of Generative AI and ChatGPT

2023-06-2024:08

HCIT: Accelerating a Healthcare Transition

2023-06-0817:43

Web Traffic Data Reveals Hidden Biopharma Trends

2023-05-3010:26

00:00

Biotech Halftime Report: A Winding Road Ahead

#box-pro-ellipsis-176583313699129{-webkit-line-clamp:2;}Biotech Halftime Report: A Winding Road Ahead

Biotech Halftime Report: A Winding Road Ahead

RBC Capital Markets

Biotech Halftime Report: A Winding Road Ahead